Literature DB >> 21954277

Measles elimination in the Americas: a comparison between countries with a one-dose and two-dose routine vaccination schedule.

Adrianne E Sever1, Jeanette J Rainey, Elizabeth R Zell, Karen Hennessey, Amra Uzicanin, Carlos Castillo-Solórzano, Vance Dietz.   

Abstract

BACKGROUND: The Region of the Americas eliminated measles in 2002 through high first-dose routine measles vaccine coverage and vaccination campaigns every 4-6 years; a second routine dose at school entry was added in some countries. The impact of this second routine dose on measles elimination was evaluated.
METHODS: Data on socioeconomic factors, demographic characteristics, vaccination coverage, and the estimated proportion of children (<15 years of age) susceptible to measles were compiled. Countries were grouped using propensity score methods, and Kaplan-Meier curves were used to compare time to measles elimination between countries with a 1-dose schedule and those with a 2-dose schedule.
RESULTS: One-dose (n = 14) and 2-dose (n = 7) countries did not differ with respect to median routine first-dose measles vaccine coverage, median coverage for 3 measles campaigns, or estimated percentage of susceptible children after routine first vaccination dose and campaigns. Compared with 1-dose countries, 2-dose countries had higher median gross national income per capita (P = .002), percentage of population living in urban areas (P = .04), and female literacy (P = .01), as well as lower infant mortality (P = .007); however, no differences in time to elimination were found.
CONCLUSIONS: One-dose and 2-dose countries had similar times to measles elimination despite socioeconomic differences between their populations. A second routine dose might not have hastened measles elimination, because threshold immunity needed to eliminate measles was achieved with high first routine dose coverage and vaccination campaigns. Further research will be needed to determine the applicability of these findings to other regions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21954277     DOI: 10.1093/infdis/jir445

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  1 in total

1.  Mass measles vaccination.

Authors:  Gholam Ali Ghorbani
Journal:  Iran J Med Sci       Date:  2012-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.